The United Kingdom and the United States have concluded a important bilateral deal that will ensure no levies on British medicine shipments going into the American market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has agreed to boost funding on pharmaceuticals through the National Health Service (NHS). This commitment guarantees that duties on these crucial exports will stay at zero for a period of three years.
This agreement follows previous threats to hike tariffs on branded drug products, with figures discussed up to 100%.
"This agreement with the United Kingdom strengthens the worldwide climate for innovative medicines and brings long-overdue fairness to U.S.–U.K. pharmaceutical trade," a release declared.
Trade Impact
Medicines constitute one of the UK's largest export categories to the United States, which is easily the biggest market for large companies like GSK and AstraZeneca.
Trade data show that in the 12 months prior to September, the UK sold drugs totaling over eleven billion pounds to the US. This value made up a significant portion of all goods exports in that period.
"This deal secures jobs, increases investment and facilitates the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary stated.
Specific UK Commitments
The deal involves several notable pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the affordability limit at which it judges new treatments to be too expensive by 25%.
- Higher Drug Budget: There is a goal to double total public funding on drugs from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Rebate Cap: The percentage manufacturers must refund to the NHS to stay within budget will be limited at 15%. In the past, refunds topped 20%.
Recent Tensions
The pact comes amid a long-running dispute between the pharmaceutical industry and the UK government over drug pricing and regulatory access.
These tensions were intensified by assertions that American customers were charged a premium for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been halted or abandoned, while substantial investments have been directed toward projects in the United States.
The Science Minister publicly accepted that the NHS needed to spend more on drugs, noting that its budget allocation on drugs had declined as a proportion of its overall budget over the previous ten-year period.
